key: cord-0728652-3tdledf1
authors: Morton, B; Barnes, KG; Anscombe, C; Jere, K; Kamng’ona, R; Brown, C; Nyirenda, J; Phiri, T; Banda, N; Van Der Veer, C; Mndolo, KS; Mponda, K; Rylance, J; Phiri, C; Mallewa, J; Nyirenda, M; Katha, G; Kambiya, P; Jafali, J; Mwandumba, HC; Gordon, SB; Cornick, J; Jambo, KC
title: In depth analysis of patients with severe SARS-CoV-2 in sub-Saharan Africa demonstrates distinct clinical and immunological profiles
date: 2021-02-20
journal: medRxiv
DOI: 10.1101/2021.02.15.21251753
sha: 3676eeaac41ad95541bab17599676163820b9366
doc_id: 728652
cord_uid: 3tdledf1

Although the COVID-19 pandemic has left no country untouched there has been limited research to understand clinical and immunological responses in African populations. Here we comprehensively characterise patients hospitalised with suspected or confirmed COVID-19, and healthy community controls. PCR-confirmed COVID-19 participants were more likely to receive dexamethasone and a beta-lactam antibiotic, and survive to hospital discharge than PCR−/IgG+ and PCR−/IgG− participants. PCR−/IgG+ participants exhibited a nasal and systemic cytokine signature analogous to PCR-confirmed COVID-19 participants, but increased propensity for Staphylococcus aureus and Streptococcus pneumoniae colonisation. We did not find evidence that HIV co-infection in COVID-19 participants was associated with mortality or altered cytokine responses. The nasal immune signature in PCR−/IgG+ and PCR-confirmed COVID-19 participants was distinct and predominated by chemokines and neutrophils. In addition, PCR−/IgG+ individuals with high COVID-19 clinical suspicion had inflammatory profiles analogous to PCR-confirmed disease and potentially represent a target population for COVID-19 treatment strategies.

The coronavirus disease 2019 pandemic has, to date, been less severe in sub-Saharan Africa compared to Europe and the Americas (1). However, clinical diagnosis, triage and treatment decisions for COVID-19 patients is particularly challenging in resource-poor settings. The increased transmissibility of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants observed in the second wave of the pandemic has made the need to address these challenges even more urgent (2) . Limited access to advanced life-preserving therapies such as mechanical ventilation, and delayed presentation to hospital is common (3) . This increases clinical and diagnostic complexity as patients may present when severely unwell, and potentially, without polymerase chain reaction (PCR)-detectable SARS-CoV-2 (4).

Cytokine dysregulation has been consistently observed in COVID-19 patients in multiple settings (5, 6) . Consequently, cytokines, including IL-6 and TNF-, have shown potential prognostic value to guide decisions on clinical management of COVID-19 (7, 8) but they lack adequate specificity. For example, IL-6 levels may be 10-to 200-fold higher for patients with the hyperinflammatory phenotype of acute respiratory distress syndrome (ARDS) compared to patients with severe COVID-19 (9) . Beyond the use of single markers, systems approaches have demonstrated immune signatures distinct to COVID-19 aligned with disease severity (10) (11) (12) . They have identified a systemic immune signature showing profoundly altered T-cells, selective cytokine/chemokine upregulation (10) and monocyte and neutrophil activation in hospitalised COVID-19 patients (11, 12) . Further, inflammatory dysregulated IL-2, IL-6, IL-10 and IL-15 are associated with COVID-19 related mortality (13) . However, there are very few studies that have investigated the respiratory tract, the initial site of infection and disease pathogenesis.

SARS-CoV-2 infection is established when the virus binds to angiotensin-converting enzyme 2 (ACE2)-expressing epithelial cells in the nasal mucosa (14) . The few studies reporting mucosal cellular or cytokine responses in COVID-19 have shown cytokine dysregulation and immune cell disruption in the lower airway, correlating with disease severity (15, 16) . However, there is a paucity of information on immune responses against SARS-CoV-2 infection in the upper airway (17) .

Minimally invasive sampling techniques of the nasal mucosa are well-tolerated, and highly useful in human challenge models of respiratory syncytial virus and Streptococcus pneumoniae (18, 19) . Given importance of the nose in SARS-CoV-2 infection (20) , understanding the host-viral interaction at the nasal mucosa could provide additional insights to understand and potentially modulate COVID-19 prognosis.

. CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 20, 2021. ; https://doi.org/10.1101/2021.02. 15.21251753 doi: medRxiv preprint Immunological responses against SARS-CoV-2 infection at the nasal mucosa are still poorly understood. Here, we analysed nasal mucosa and peripheral blood samples from a comprehensively characterised cohort of patients admitted to hospital with suspected and/or confirmed COVID-19.

These patients were compared with adult healthy community controls. Immunological parameters were studied using 38-multiplex cytokine assays and flow cytometry, while profiling of respiratory pathogens was done using a 33-multiplex polymerase chain reaction (PCR) respiratory pathogen diagnostic panel. Our study provides insights on the cytokine responses in the nasal mucosa following SARS-CoV-2 infection in severe COVID-19 patients and the potential importance of additional confirmatory antibody tests for diagnosis of SARS-CoV-2 PCR-negative patients with high clinical suspicion of COVID-19.

Between 21 st April 2020 and 25 th September 2020, 87 patients (median age 47 years, IQR: presenting with severe acute respiratory infection (SARI) were recruited, of whom 60 (69.0%) were male (Table 1) . SARS-CoV-2 was confirmed by nucleic acid amplification (NAAT) in 41 participants (classified as 'PCR-confirmed COVID-19") ( Figure 1a ). The remaining 46 participants with suspected disease were NAAT negative (Figure 1a ). Of these, 25 were IgG positive against spike protein 2 and nucleoprotein on serological testing. Using nucleic acid amplification (NAAT) and antibody test results, we reclassified the patient groups into PCR-confirmed COVID-19, PCR-/IgG+ SARI (n=25) and PCR-/IgG-SARI (n=21) participants ( Figure 1b ). In addition, we recruited 25 ambulatory healthy volunteers. Patient demographics and clinical characteristics are reported in Table 1 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

We investigated the cytokine response in nasal lining fluid and serum of our four participant groups.

Our analysis was limited to 25 PCR-confirmed COVID-19 participants (who were IgG positive), 16 PCR-/IgG+ SARI participants, 11 PCR-/IgG-SARI participants and 25 healthy controls, from whom we had paired nasal lining fluid and serum samples. We measured the concentration of 37 cytokines (and sCD40L) in paired nasal lining fluid and serum samples of the four study groups ( Figure S2 and S3). We found altered cytokine levels in both nasal lining fluid and serum of PCR-confirmed COVID-19 participants, PCR-/IgG+ SARI participants and PCR-/IgG-SARI participants, relative to healthy controls ( Figure 2a) . Specifically, high concentrations of inflammation-related cytokines were common among all the patient groups compared to healthy controls, including IL-1, IL-1, IL-6, MIP-1 and TNF- in nasal lining fluid, and raised levels of IL-6, IL-10, IP-10 and IL-15 in serum ( Figure 2b ).

In comparison to PCR-confirmed COVID-19 (nasal, n=7; serum, n=5) and PCR-/IgG+ SARI participants (nasal, n=8; serum, n=8), PCR-/IgG-SARI participants (nasal, n=11; serum, n=14) had an increased number of cytokines with higher concentrations than healthy controls in nasal lining fluid and serum ( Figure 2a-b) . In comparison to PCR-/IgG-SARI participants (nasal, n=0; serum, n=2), PCR-confirmed COVID-19 (nasal, n=9; serum, n=5) and PCR-/IgG+ SARI participants (nasal, n=5; serum, n=8) had an increased number of cytokines with lower concentrations than healthy controls in nasal lining fluid and serum (Figure 2a circulation. This also suggests that PCR-confirmed COVID-19 and PCR-/IgG+ SARI participants may be presenting at different stages of the SARS-CoV-2 infection spectrum.

Severe COVID-19 is associated with a distinct nasal and serum cytokine profile to non-COVID-19

Due to the similarity of the cytokines induced in PCR-/IgG+ SARI participants relative to PCRconfirmed COVID-19 (Figure 2a- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 20, 2021. ; https://doi.org/10.1101/2021.02.15.21251753 doi: medRxiv preprint the positive SARS-CoV-2 IgG serology result (Figure 2b ), we explored if clinical reclassification of PCR-/IgG+ SARI participants as COVID-19 disease was warranted. We hypothesised that using an unsupervised analysis the immunological phenotype of PCR-/IgG+ SARI participants would be analogous to PCR-confirmed COVID-19 participants, but distinct from PCR-/IgG-SARI participants and healthy controls. First, we performed a principal-component analysis (PCA) of all the analytes for the patients and controls in either nasal lining fluid and serum. In both compartments, PCA segregated together PCR-confirmed COVID-19 participants and PCR-/IgG+ SARI participants, away from healthy controls, whereas PCR-/IgG-SARI participants appeared as a heterogeneous group ( Figure 3a and Figure 3b ). Second, we analysed the active cytokine functional families in nasal and serum, to ascertain whether PCR-/IgG+ SARI participants had immunological pathways similar to PCR-confirmed COVID-19 participants. Analysis of the active cytokine functional families has previously been used to define immune signatures unique to COVID-19 (10) (11) (12) . To aid interpretation of the data, the cytokines were divided into functional groups including growth factors, chemokines, adaptive, pro-inflammatory and anti-inflammatory. In both nasal lining fluid and serum, differential interaction of cytokines was observed among the study groups, with the cytokine interaction profile being generally similar between PCR-/IgG+ SARI participants and PCR-confirmed COVID-19

participants, but distinct from PCR-/IgG-SARI participants and healthy controls (Figure 3c and Figure   3d ). Specifically, in the nasal lining fluid, we observed a strong interaction in the chemokine family, including between chemokines and growth factors, in PCR-confirmed COVID-19 participants and PCR-/IgG+ SARI participants (Figure 3c ). In the serum, fewer interactions were observed, but still a distinct pattern in the adaptive cytokine family in PCR-confirmed COVID-19 participants and PCR-/IgG+ SARI participants ( Figure 3d) . Third, in a subset of participants, we explored the nasal immune cellular profile in PCR-confirmed COVID-19 and PCR-/IgG+ SARI participants compared to healthy controls. We observed a higher frequency of neutrophils and lower frequency of CD3 + T cells in the nasal mucosa of PCR-confirmed COVID-19 and PCR-/IgG+ SARI participants compared to healthy controls ( Figure 4) . Collectively, the findings demonstrate that the PCR-/IgG+ SARI participants induced similar immunological pathways to PCR-confirmed COVID-19 participants but that this was distinct from PCR-/IgG-SARI participants. Taken together, these findings suggest that clinical reclassification of COVID-19 status could be warranted.

PCR-confirmed COVID-19 participants exhibit reduced propensity for bacterial colonisation Due to the differential clinical management pathways experienced by the PCR-confirmed COVID-19

and PCR-/IgG+ SARI participants in the study, including beta-lactam antibiotic usage and steroid treatment, we sought to determine the presence of other respiratory pathogens in NP/throat swabs. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Bacterial co-infection with SARS-CoV-2 is associated with adverse outcomes (21, 22) . A total of 80 participants from the patient groups (from whom we had complete clinical and antibody data) were tested for presence of respiratory pathogens using the fast-track diagnostics (FTD)-33 respiratory panel. The median time from admission to NP/throat swab collection for the respiratory panel testing was three days (IQR 1-5). Using the FTD-33 panel we identified 12 other respiratory pathogens present in our patient population, in addition to SARS-CoV-2 and HIV ( Figure 4a ). Overall, 74% (59/80) of participants had one or more pathogen(s) (Figure 5a ). Presence of bacterial pathogens was common, identified in 74% (59/80), but viral pathogens (excluding HIV) was only present in 14% (11/80) of participants (Figure 5a and S4a). The most common respiratory pathogen across all study groups was Klebsiella pneumoniae ( Figure S4b) [42%], p=0.071) than PCR-/IgG+ SARI participants (Figure 5b-c) . These findings show that presence of bacterial pathogens in the upper respiratory tract was very common in our hospitalised patient cohort. They also show that PCR-confirmed COVID-19 patients had lower proclivity for S. aureus and S. pneumoniae colonisation than PCR-/IgG+ SARI participants, potentially impacted by increased use of beta-lactam antibiotic usage in this study group.

Association of HIV co-infection with cytokine responses, respiratory bacterial prevalence and clinical outcomes in COVID-19 patients In our cohort, people living with HIV were distributed across the patient groups (Table 1) . We therefore explored the influence of HIV co-infection on the cytokine responses, presence of respiratory pathogens, and mortality. We reclassified the PCR-/IgG+ SARI participants as COVID-19 and combined them with the PCR-confirmed COVID-19 to form a single COVID-19 patient group.

There were no statistically significant differences in the levels of cytokines in nasal lining fluid and serum between HIV-infected and HIV-uninfected COVID-19 participants (Figure 6a is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint HIV co-infection in COVID-19 participants was associated with altered cytokine responses, increased prevalence of respiratory pathogens nor increased mortality.

We provide the first clinical and immunological analysis to our knowledge of suspected or confirmed COVID-19 patients admitted to hospital in a low-income sub-Saharan African country. We identified individuals with manifestations of COVID-19 who were SARS-CoV-2 RT-qPCR negative but IgG positive that showed immunological profile analogous to PCR-confirmed COVID-19 participants. This was distinct from PCR-/IgG-SARI participants and healthy controls. The PCR-/IgG+ SARI subgroup experienced poorer clinical outcomes compared to PCR-confirmed participants, potentially due to later hospital presentation or failure to access effective treatment for COVID-19. In our cohort, access to drugs such as dexamethasone in patients suspected of COVID-19 was determined by RT-qPCR test positivity and not SARS-CoV-2 IgG antibody status. Identification of this subgroup of SARI patients highlights the importance for further optimisation of triage and clinical treatment pathways in the era of COVID-19, especially in low-resource settings.

Low cost, effective and pragmatic interventions such as dexamethasone have been widely adopted and incorporated into treatment pathways (24) . The COVID-19 treatment guidelines recommend against dexamethasone administration for patients who do not require supplemental oxygen (25) but there are no specific recommendations for how COVID-19 should be diagnosed. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Cytokine dysregulation is a hallmark of severe COVID-19 (27) . Consistent with published studies (5, 6), we observed high concentrations of inflammation-associated cytokines, including IL-6, TNF-, IP-10, IL-10, IL-1 and IL-1 in serum and nasal lining fluid from PCR-confirmed COVID-19 patients.

However, elevation of these cytokines was also observed in serum from non-COVID SARI participants. Instead, the induction of the chemokine family in the nasal mucosa was distinctive to severe COVID-19 and was distinct from systemic circulation. The predominance of the chemokine family was in line with the infiltration of neutrophils in the upper airway observed in this cohort and others (28, 29) . A study that performed transcriptomic analysis on paired upper and lower respiratory tract samples from two COVID-19 patients and showed very high congruency in the majority of the cell types between the sites (28), suggesting a shared immune response between the sites. Consistent with this suggestion, the chemokine-dominated signature and neutrophil infiltration observed in the upper airway of severe COVID-19 patients in our study was similar to that reported in the lower airway (15, 16, 30) . Neutrophils promote inflammation and play a pathogenic role in COVID-19 (31) . Circulating neutrophils from severe COVID-19 patients show exaggerated oxidative burst, NETosis and phagocytosis relative to healthy controls (32) . Measurement of dysregulated neutrophil function in the nose was not possible in this study, but presence of NETs has been reported in the lungs of deceased severe COVID-19 patients with acute respiratory distress syndrome (ARDS) (33) , where they are thought to drive severe pulmonary complications of COVID- 19 . In ARDS patients, low levels of VEGF in the lower airway are a marker of acute lung injury (34) , and in our study, severe COVID-19 patients exhibited distinctively low concentrations of VEGF in nasal lining fluid. Collectively, this suggests that the nasal mucosa could provide a snapshot of immunological activity in the lung in patients with COVID-19. This warrants further investigation as nasal sampling is well tolerated and more easily accessible than lower airway sampling.

Some of the major features of severe COVID-19 are lymphopenia and neutrophilia in the systemic circulation (35, 36) . As such, the neutrophil to lymphocyte ratio has been shown to have prognostic value, predicting those at high risk of severe disease or death (37) . However, the mechanisms behind lymphopenia and neutrophilia during COVID-19 are still not well understood. Interestingly, in our study, concentrations of IL-3 and Flt-3L were distinctively altered in severe COVID-19 participants compared to non-COVID-19 SARI participants. Specifically, in severe COVID-19 participants, IL-3 was detected at very high levels in the nasal lining fluid, while Flt-3L was repressed in serum. IL-3 and Flt-3L are key cytokines involved in haematopoiesis of leukocytes (38, 39) . IL-3 induces expansion and generation of myeloid cells (38, 39) , while Flt-3L binds to Flt-3 and activates common lymphoid progenitor cells to increase the number of lymphocytes (40, 41) . Alterations in these cytokines in . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 20, 2021. ; https://doi.org/10.1101/2021.02.15.21251753 doi: medRxiv preprint mouse models are associated with dysregulated haematopoiesis and altered leukocyte cellularity (39, 41) . Therefore, it is plausible that high levels of IL-3 and repressed levels of Flt-3L could contribute to the high neutrophil to lymphocyte ratio and altered leukocyte numbers observed in severe COVID-19 patients.

Due to the high HIV prevalence in our setting, we were able to explore the impact of HIV co-infection on COVID-19. While data from the United Kingdom and South Africa suggests an increased risk of mortality in HIV-infected COVID-19 patients (42-44), a systematic review and data from the United States did not demonstrate this association (45) (46) (47) . In our cohort, we did not find statistically significant differences in the cytokine responses, prevalence of respiratory pathogens nor mortality between HIV-infected and HIV-uninfected COVID-19 participants. The small sample size of this study limits our ability to adjust for the multiple potential confounders that could impact on clinical outcomes, including age, gender, co-morbidities, antiretroviral therapy status and HIV viral load.

Larger cohort studies with comprehensive immunological data and sufficient power to adjust for multimorbid diseases are required to provide further clarity on this issue.

Despite the strengths of this study including use of an internationally recognised protocol with standardised data collection tools, well-characterised clinical cohort and paired nasal and systemic immune responses, our study had some limitations. Due to programmatic constraints, it was not feasible to conduct longitudinal sampling among our participants to monitor recovery and response to therapy. In addition, whilst the majority of participants were recruited within the first 72 hours of admission, a proportion of our participants were recruited later in their hospital admission. Lack of critical care facilities precluded universal recruitment and sampling in the most severe cases, and our patient population may therefore not be entirely representative of all participants with SARS-CoV-2 induced SARI. Furthermore, we cannot exclude secondary bacterial infections as potential contributors to increased mortality in the PCR-/IgG+ SARI participants, as we did not have access to blood culture or autopsy results. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

We prospectively recruited patients using the tier one sampling strategy from the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) Clinical Characterisation Protocol (CCP) (48). Briefly, the CCP is a standardised protocol that enables data and biological samples to be collected rapidly in a globally harmonised manner for any severe respiratory infection of public health interest (48). Patients over 18 years old were approached for informed written consent if they met inclusion criteria: severe acute respiratory infection (SARI) with suspected or confirmed SARS-CoV-2. For patients who lacked capacity, assent was sought from a proxy as per our ethical approvals. Subsequently, informed consent was obtained retrospectively from these patients, where possible. Patients were excluded from recruitment if they or their proxy declined to participate. We aimed to recruit within 72hrs of hospital admission. Nasopharyngeal airway, nasosorption, nasal biopsy and peripheral blood samples were collected at the point of patient recruitment ( Figure S1 ). Thereafter, patients were followed up until hospital discharge or death. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

Peripheral blood collected in serum separation tubes underwent centrifugation at 500g for 8 mins to isolate serum. Serum was stored at -80°C. To measure SARS-CoV-2 antibodies, we used a commercial enzyme linked-immunosorbent assay (ELISA) targeting Spike (S2) and Nucleoprotein is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

The authors thank all study participants and the staff of the Queen Elizabeth Central Hospital (QECH) for their support and co-operation during the study. This work was supported by the UK Foreign, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

The authors declare no competing interests.

. CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Table 1 : Clinical Characteristics. PCR+ is RT-qPCR confirmed SARS-CoV-2 severe acute respiratory infection (SARI); PCR-/IgG-is patients with SARI who were RT-qPCR negative but IgG positive for SARS-CoV-2; and PCR-/IgG-is patients with SARI who were both RT-qPCR negative and IgG negative for SARS-CoV-2. Healthy controls were ambulant patients with no intercurrent illness who attended an outpatient clinic appointment. *Proportion (%) positivity calculated using the denominator for individual variables (unknown status classified as missing data). ISARIC 4C score calculated using six clinical variables available within dataset as urea and C-reactive protein were not available. UVA; universal vital assessment score (low income country validated clinical severity score). α: Fisher's exact test; β: Kruskall-Wallis test. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 20, 2021. ; GRO   IL_10   IL_15   IL_1RA   IL_1A  IL_1B   IL_2   IL_3   IL_5   IL_6  IP_10   MCP_1   TNF_B   PCR-confirmed COVID-19 PCR-IgG+ SARI PCR-IgG-SARI Nasal lining fluid Groups   CMT1XA  CMT172  CMT1QB  CMT16H  CMT1KH  CMT1X6  CMT1XF  CMT1XM  CMT176  CMT166  CMT16V  CMT174  CMT175  CMT15E  CMT15Y  CMT16F  CMT1KM  CMT1XL  CMT15R  CMT16M  CMT15H  CMT15L  CMT15M  CMT16A  CMT16G  CMT16J  CMT16R  CMT16S  CMT16U  CMT170  CMT1KP  CMT1PY  CMT16P  CMT1X5  CMT162  CMT169  CMT1KJ  CMT15F  CMT15K  CMT16I  CMT1KE  CMT1KG  CMT15T  CMT15W  CMT15Z  CMT16B  CMT16E  CMT16L  CMT177  CMT15G  CMT15I  CMT15P  CMT160  CMT163  CMT164  CMT165  CMT167  CMT16D  CMT16N  CMT16X  CMT16Y  CMT171  CMT1KF  CMT1KK  CMT15J  CMT15U  CMT161  CMT16K  CMT173  CMT15V  CMT15X  CMT16Z  CMT1KI  CMT1KN  CMT15S  CMT16C  CMT16T  CMT16W  CMT1KL 

Update on Covid

Africa Succeeded Against COVID-19's First Wave, but the Second Wave Brings New Challenges

Effect of an Early Resuscitation Protocol on In-hospital Mortality Among Adults With Sepsis and Hypotension: A Randomized Clinical Trial

At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data

Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China

Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm

Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome

An inflammatory cytokine signature predicts COVID-19 severity and survival

Is a "Cytokine Storm" Relevant to COVID-19?

A dynamic COVID-19 immune signature includes associations with poor prognosis

A distinct innate immune signature marks progression from mild to severe COVID-19

Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19

An immune-based biomarker signature is associated with mortality in COVID-19 patients

ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

Bronchoalveolar inflammation in COVID-19 patients: a correlation with clinical outcome

The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection

Neutrophilic inflammation in the respiratory mucosa predisposes to RSV infection

Inflammation induced by influenza virus impairs human innate immune control of pneumococcus

SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract

Impact of the COVID-19 Pandemic on Invasive Pneumococcal Disease and Risk of Pneumococcal Coinfection with SARS-CoV-2: prospective national cohort study

Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study

Genomic investigation of a suspected multi-drug resistant <em>Klebsiella pneumoniae</em> outbreak in a neonatal care unit in sub-Saharan Africa

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report. The New England journal of medicine

Pragmatic Recommendations for Therapeutics of Hospitalized COVID-19 Patients in Lowand Middle-Income Countries. The American journal of tropical medicine and hygiene. 2020. 26. WHO. Clinical management of COVID-19 interim guidance 2020

Cytokine release syndrome in severe COVID-19

COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis

Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19

Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients

SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology

Increased peripheral blood neutrophil activation phenotypes and NETosis in critically ill COVID-19 patients

Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19

A role for vascular endothelial growth factor in acute and resolving lung injury

Clinical and immunological features of severe and moderate coronavirus disease 2019

Clinical Characteristics of Coronavirus Disease 2019 in China

Neutrophil-to-Lymphocyte Ratios Are Closely Associated With the Severity and Course of Non-mild COVID-19

IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling

Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis

Preclinical Evaluation of Flt3 Ligand to Improve T Cell Adaptive Immune Response During Sepsis

Key role of flt3 ligand in regulation of the common lymphoid progenitor but not in maintenance of the hematopoietic stem cell pool

Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK): a prospective observational study

HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform

Risk factors for COVID-19 death in a population cohort study from the Western Cape Province

Coronavirus disease 2019 (COVID-19) outcomes in HIV/AIDS patients: a systematic review

and People Living With Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in

HIV infection alters SARS-CoV-2 responsive immune parameters but not clinical outcomes in COVID-19 disease